Metabolism

Items 201-250 of 6503

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. IDH1 inhibitor

    AGI-5198, also know as IDH-C35, is the a very potent and selective mutant IDH1 inhibitor that was shown to potential anticancer activity.
  2. IDH2 R140Q inhibitor

    AGI-6780 is a potent, selective inhibitor of mutant IDH2 with an IC50 value of 23 nM.
  3. AR7

    RARα antagonist.

    AR7 was developed as a highly potent and selective enhancer of the chaperone-mediated autophagy (CMA) through antagonizing RARα.
  4. PDE inhibitor

    Forskolin is a cell-permeable diterpenoid that possesses anti-hypertensive, positive inotropic, and adenylyl cyclase activating properties.
  5. IDH1 R132H inhibitor

    IDH-C227 is a potent and selective IDH1 R132H inhibitor.
  6. NAMPT activator

    P7C3 is neurogenic and protects new neurons against apoptosis. It protects newborn neurons in the dentate gyrus and stimulates the growth of new neurons.
  7. NAMPT activator

    (R)-P7C3-Ome is a methoxy derivative of parent compound P7C3, an aminopropyl carbazole that exhibits antidepressant and neuroprotective activities.
  8. Homogentisic acid is a specific metabolite in urine and serum, which is used for diagnosis of alkaptonuria.
  9. AhR antagonist

    StemRegenin 1 (SR1) is a cell-permeable purine derivative that acts as an antagonist of aryl hydrocarbon receptor and promotes the self-renewal of hematopoietic stem cells (HSCs).
  10. MAO-A inhibitor

    Salsolidine is a tetrahydroisoquinoline alkaloid, acts as a stereoselective competitive MAO A inhibitor.
  11. PDE9A inhibitor

    BI-409306 is a potent and selective PDE9A inhibitor, with an IC50 of 52 nM.
  12. CRM1 Inhibitor

    KPT185 is a selective CRM1 inhibitor. KPT-185 significantly inhibits leukemia cell proliferation with IC50 ranging from 100 nM to 500 nM, and induces cell-cycle arrest and apoptosis of AML cell lines and primary AML blasts.
  13. HIF inhibitor

    BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I.
  14. IDO1 inhibitor

    INCB024360 is an orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase (IDO1), with potential immunomodulating and antineoplastic activities.
  15. PDE2A inhibitor

    PF-05180999 is a phosphodiesterase 2A (PDE2A) inhibitor, with an IC50 of 1.6 nM.
  16. RAR agonist

    TTNPB enhances reprogramming efficiency in chemically induced pluripotent stem cells (CiPSCs).
  17. oxidative phosphorylation inhibitor

    Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma. Gboxin inhibits the activity of F0F1 ATP synthase. Antitumour activity.
  18. squalene synthase inhibitor

    RPR107393 free base is a selective squalene synthase inhibitor, which inhibits rat liver microsomal squalene synthase with an IC50 of 0.8??0.2 nM.
  19. FASN inhibitor

    Denifanstat (TVB-2640) is a Fatty Acid Synthase (FASN) inhibitor extracted from patent WO2012122391A1, compound 152, has an IC50 of 0.052 μM and an EC50 of 0.072 μM.

  20. Cytochrome P450 inhibitor

    Talarozole R enantiomer inhibits the metabolism of retinoic acid by blocking the cytochrome P450 enzyme isoform CYP26, a retinoic acid hydroxylase.
  21. alpha-glucosidase I inhibitor

    Celgosivir is an alpha-glucosidase I inhibitor for the potential treatment of HCV infection.
  22. PDE9 inhibitor

    PF-04447943 is a potent, selective brain penetrant PDE9 inhibitor that increased indicators of hippocampal synaptic plasticity and improved cognitive function in a variety of cognition models in both rats and mice.
  23. L-Valyl-L-phenylalanine (Valylphenylalanine; H-VAL-PHE-OH) has been reported as biocompatible polymer.
  24. peripheral benzodiazepine receptor agonist

    AC-5216 is a translocator protein [TSPO (18 kDa)] ligand.
  25. Endothelial lipase(EL) inhibitor

    XEN445 is a potent and selective EL inhibitor(IC50=0.237 uM), that showed good ADME and PK properties, and demonstrated in vivo efficacy in raising plasma HDLc concentrations in mice.
  26. WNK inhibitor

    WNK-IN-11 is an allosteric With-No-Lysine (WNK) kinase inhibitor, with an IC50 of 4 nM for WNK1.
  27. glucokinase activator

    PF-04937319 is a glucokinase activator (GKA) with EC50 value of 154.4 ?μM, one of the most promising strategies for the treatment of type 2 diabetes mellitus.
  28. Benzo[a]pyrene shows lung carcinogenicity in animal models, and it is frequently used in chemoprevention studies.
  29. GA mitochondrial matrix inhibitor

    Gamitrinib TPP is a GA mitochondrial matrix inhibitor. Gamitrinib TPP is offered as the hexafluorophosphate salt.

  30. dehydroorotate dehydrogenase inhibitor

    Manitimus is an inhibitor of dehydroorotate dehydrogenase, and a potent immunosuppressive drug.
  31. TB5

    hMAO-B inhibitor

    TB5 is a potent, selective and reversible inhibitor of hMAO-B with a Ki value of 0.11??0.01 μM.
  32. hormone sensitive lipase (HSL) inhibitor

    HSL-IN-1 (compound 24b) is a potent and orally active hormone sensitive lipase (HSL) inhibitor (IC50=2 nM) with a significantly reduced reactive metabolite liability.
  33. N2-methylguanosine is a modified nucleoside that occurs at several specific locations in many tRNA's.
  34. SRPK inhibitor

    SRPIN340 is a cell-permeable isonicotinamide that acts as an ATP-competitive SRPK1-selective inhibitor (IC50 = 0.14 and 1.8 μM, respectively, against mSRPK1 and mSRPK2) with much reduced activity against 143 other kinases.
  35. endogenous trace amine neuromodulor

    m-Tyramine is an endogenous trace amine neuromodulor. m-Tyramine has effects on the adrenergic and dopaminergic receptor.
  36. DGAT-1 inhibitor

    AZD3988 is a diacylglycerol acyl transferase-1 (DGAT-1) inhibitor with IC50s of 6, 5, 11 nM for human, rat, mouse, respectively.
  37. Megakaryocytes/platelets inducing agent is an inducing agent for megakaryocytes and/or platelets from pluripotent stem cells, the inducing agent being useful in treating diseases involving thrombopenia.
  38. Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) inhibitor

    Rilapladib is a selective Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) inhibitor with an IC50 of 230 pM.
  39. PPARδ agonist

    Pparδ agonist 2 is a PPARδ agonist extracted from patent WO 2016057656 A1.
  40. biomarker

    N6-Etheno 2'-deoxyadenosine is a reactive oxygen species (ROS)/reactive nitrogen species (RNS)-induced DNA oxidation product, used as a biomarker to evaluate chronic inflammation and lipid peroxidation in animal or human tissues.
  41. PDE5 inhibitor

    Udenafil is a PDE5 inhibitor used in urology to treat erectile dysfunction.
  42. MAO-B inhibitor

    Safinamide is a highly selective and reversible monoamine oxidase type B (MAO-B) inhibitor that increases neostriatal dopamine concentration.
  43. SCD1 inhibitor

    A939572 is a potent, and orally bioavailable stearoyl-CoA desaturase1 (SCD1) inhibitor with IC50 values of <4 nM and 37 nM for mSCD1 and hSCD1, respectively.
  44. Anserine is a dipeptide found in skeletal muscle of vertebrates.
  45. PDE3 inhibitor

    Vesnarinone is a quinolinone derivative, and its pharmacodynamic effects include inhibition of phosphodiesterase III (PDE3) activity, increases in calcium flux and decreases in potassium flux.
  46. Uridine triphosphate (UTP;Uridine 5'-triphosphate) is a nucleotide that regulates the functions of the pancreas in endocrine and exocrine secretion, proliferation, channels, transporters, and intracellular signaling under normal and disease states.
  47. NAMPT Inhibitor

    GNE-617 is a potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with IC50 value of 5nM.
  48. LDHA Inhibitor

    AZ33 is a LDHA Inhibitor.
  49. leukotriene biosynthesis inhibitor

    MK-886 is an inhibitor of leukotriene biosynthesis (IC50 = 3 nM in human polymorphonuclear leukocytes).
  50. 15-LO inhibitor

    PD146176 (NSC168807) is a 15-Lipoxygenase (15-LO) inhibitor, which inhibits rabbit reticulocyte 15-LO with a Ki of 197 nM. PD146176 (NSC168807) has a dramatic effect in reducing atherogenesis.

Items 201-250 of 6503

Page
per page
Set Descending Direction